Colorectal Cancer
Conditions
Keywords
Multilevel intervention, Stepped wedge design, Implementation strategy, Federally qualified health center
Brief summary
Screening for colorectal cancer (CRC) not only detects disease early when treatment is more effective but also prevents cancer by finding and removing precancerous polyps. Because many of our nation's most disadvantaged and vulnerable individuals obtain health care at federally qualified health centers, these centers play a significant role in increasing CRC screenings among the most vulnerable populations. Furthermore, the full benefits of cancer screenings must include timely and appropriate follow-up of abnormal results. Thus, the purpose of this study is to implement a multilevel intervention to increase rates of CRC screenings, follow-ups, and referrals-to-care in federally qualified health centers (FQHCs). Also, we will examine the implementation strategies used to support the implementation process and their contribution to the adoption, implementation, and sustainment of the multilevel intervention. The multilevel intervention will target three different levels of influences: organization, provider, and individual. It will have multiple components, including provider and staff education, provider reminder, provider assessment and feedback, patient reminder, and patient navigation. This study is a multilevel, three-phase, stepped wedge cluster randomized trial with four clusters of clinics from four different FQHCs. Our FQHC partners together have 40 primary care clinics and 130 primary care providers. During Phase 1, there will be a 3-month waiting period during which no intervention components will be implemented. After the 3-month waiting period, we will randomize two clusters of clinics to cross from the control to the intervention and the remaining two clusters to follow three months later. All clusters of clinics will stay at the same phase for nine months, followed by a 3-month transition period, and then cross over to the next phase. In Phase 1, we will implement provider and staff education sessions. In Phase 2, we will add provider reminders, patient reminders, and provider assessment and feedback. We will add patient navigation during the last phase. Single level interventions are often insufficient at leading to sustainable changes. Multilevel interventions are needed to address multilevel contextual influences simultaneously. How to take advantage of multilevel interventions and how to implement such interventions and evaluate their effectiveness are the ultimate goals of this study.
Detailed description
A. BACKGROUND A1. Colorectal cancer control and FQHCs Screening for CRC not only detects disease early when treatment is more effective but also prevents cancer by finding and removing precancerous polyps. Despite strong evidence to support CRC screening, nationally, only 68.8% of adults had up to date screening in 2018 \[1\]. This figure is even lower among racial/ethnic minorities and people who live in poverty \[2-5\]. Racial/ethnic minorities and people with low social-economic status often lack health insurance and a regular source of care. These populations also disproportionately receive health care in safety-net settings, such as federally qualified health centers (FQHCs) \[6-7\]. In 2018, FQHCs served 28 million patients, of whom 23% were uninsured, 63% were racial/ethnic minorities, and 91% were living below 200% poverty level \[8\]. Thus, FQHCs play a significant role in increasing CRC screening among the most vulnerable populations. A2. Challenges of colorectal cancer control in FQHCs Due to the cost and limited availability of specialty services combined with patient preferences, FQHCs often promote non-invasive screening methods, such as fecal occult blood test (FOBT) or fecal immunochemical tests (FIT), as the modality for screening \[9-12\]. To achieve the benefits of CRC screening using FOBT/FIT, timely follow-up of positive results must occur. While no national estimates of the proportion of individuals without follow-up diagnostic evaluation after receiving a positive FOBT/FIT exist, several studies report follow-up rates ranging from less than 50% to 90% within one year of a positive test \[13-22\], with integrated health care systems exhibiting higher follow-up rates by 12 months (82%-86%) compared to FQHCs (56%-58%) \[23-24\]. A3. Multilevel influences on cancer screening behavior Individuals live and seek care in a complex environment, and multiple levels of contextual influences may affect individual decisions and actions \[25-26\]. Multilevel interventions target changes in more than one contextual level (e.g., organization, provider, and patient levels) to influence health behavior, health care practice, and health outcomes \[27-28\]. Although the call for multilevel interventions has increased \[29-31\], there is still a lack of evidence addressing how to implement multilevel interventions or how interventions at multiple levels interact and affect health outcomes. B. STUDY OBJECTIVES The overall objective of this study is to provide the evidence base for multilevel interventions that increase rates of CRC screening, follow-up, and referral-to-care at federally qualified health centers, and to understand how to improve the adoption, implementation, and sustainment of these interventions. In this study, we will test the effectiveness of our multilevel intervention while simultaneously observing and gathering information on the implementation process. The selection of our multilevel intervention components is based on extensive literature review, the strength of evidence, and findings from our previous studies and projects. The multilevel intervention will target three different levels of influence (organization, provider, and individual) to improve rates of CRC screening, follow-up, and referral-to-care at our partner FQHCs. Our multilevel intervention will have multiple components, including provider and staff education, provider reminder, provider assessment and feedback, patient reminder, and patient navigation. The aims this study are fourfold: (1) use a stepped wedge design to implement a multilevel intervention in three phases, (2) collect quarterly data to track changes over time, (3) evaluate the implementation process and the effectiveness of implementation strategies through observations, interviews, and annual survey, and (4) evaluate the effectiveness of the multilevel intervention using multilevel and longitudinal modeling. C. METHODS CRC screening and follow-up processes are complex and include several steps and interfaces. However, very few interventional studies have simultaneously targeted patient-, provider-, and organization-level factors. Interventions that focus on reducing barriers across several levels will likely be more effective for increasing rates of CRC screening, follow-up, and referral-to-care. C1. Multilevel Intervention and Implementation Strategy Provider Level Component Provider education Numerous studies indicate the importance of physician recommendation in influencing a patient's CRC screening decision \[31-44\], and this factor is a primary predictor for patient adherence with screening guidelines \[45-47\]. The research team will provide tailored education and guidance on best practices for participating health professionals. The educational sessions will focus on CRC risk assessment, screening guidelines, cultural competency, shared decision making, and communication skills using an academic detailing approach. The academic detailing approach involves trained experts visiting health care professionals in their settings to provide tailored education and guidance on best practices, which have shown to have a significant effect on increasing rates of CRC screening \[48-53\]. Each session will last about 15 to 20 minutes and will take place during routine staff and provider meetings. These academic detailing sessions will be ongoing throughout the study period. Provider assessment and feedback We will combine academic detailing with practice facilitation, which includes assessment and feedback on aggregate and individual provider screening behavior and practice performance \[54\]. The reports will include CRC screening order rates, screening completion rates, follow-up rates for abnormal results, and referral to oncology care. Providers will be able to see each other's performances, which allows providers to compare and learn from each other's successes. Provider reminder Given the multitude of competing priorities during a patient encounter, CRC screening recommendations can be overlooked. A provider prompt generated electronically or manually by staff members will be implemented to remind providers to screen their eligible patients. Provider prompts have been shown to increase CRC screening rates \[55\]. C2. Organization and Individual Level Component Patient reminder Provider recommendation alone does not guarantee the completion of CRC screening, which involves patient compliance. We will implement a patient reminder component using a text-based platform, also known as short message service (SMS), to engage and remind patients to complete the screening. For patients who use colonoscopy as a screening method, the SMS will also include instruction on bowel preparation and dietary restrictions five days before the procedure. Studies have demonstrated that SMS patient reminders not only had a positive impact on screening rates but also improved the quality of bowel preparation \[56-61\]. Patient navigation Patient navigation services will address both organization and individual influences. Patient navigation focuses on eliminating barriers by guiding a patient through a complex healthcare system, addressing education, sociocultural, and logistical needs using trained staff. We will hire and train two full-time CRC navigators and adapt and modify the well-studied New Hampshire Colorectal Cancer Screening Program (NHCRCSP) Patient Navigator Model \[62-64\]. C3. Implementation Strategy The effectiveness of an intervention, in part, depends on the strength of the implementation process. We will conduct a pre-implementation organizational readiness assessment (ORA). We will use the Consolidated Framework for Implementation Research (CFIR) to guide our ORA. We will conduct key informant interviews with health system leadership and clinic leaders to evaluate: 1) current CRC screening workflow, 2) CRC data capturing and validation process, and 3) capacity and resources available to support the implementation. Also, we will conduct a readiness survey with clinical providers and support staff to assess organizational climate and culture. Our 29 survey items were adapted and modified from validated instruments65-68 that measured CFIR constructs using a Delphi method. Effective strategies to support the implementation process is critical. Implementation strategies are actions taken to enhance the adoption, implementation, and sustainability of evidence-based interventions. We will use different implementation strategies to implement our multilevel intervention. Finally, we will implement our multilevel, multicomponent intervention in three phases along the CRC screening continuum. In Phase 1, we will collect baseline data and implement provider and staff education sessions. In Phase 2, we will add provider reminders, patient reminders, and provider assessment and feedback. We will add patient navigation during the last phase. C4. Study Design This study is a multilevel, three-phase, stepped wedge cluster randomized trial with four clusters of clinics from four different FQHCs. Our FQHC partners together have 40 primary care clinics and 130 primary care providers. During Phase 1, there will be a 3-month waiting period during which no intervention components will be implemented. After the 3-month waiting period, we will randomize two clusters of clinics to cross from the control to the intervention and the remaining two clusters to follow three months later. All clusters of clinics will stay at the same phase for nine months, followed by a 3-month transition period, and then cross over to the next phase. In Phase 1, we will implement provider and staff education sessions. In Phase 2, we will add provider reminders, patient reminders, and provider assessment and feedback. We will add patient navigation during the last phase. C5. Study Sites We will partner with four FQHCs, two in Illinois and two in Indiana. Together, our FQHC partners have 40 primary care clinics and 130 primary care providers and served 162,000 individual patients in 2018. Of the 162,000 patients, 78% were racial minorities, 93% live at or below 200% poverty, and 17% were uninsured. The CRC screening rates among our partners range from 25% to 43%. C6. Process Evaluation We will assess the potential causal and contextual factors that may be associated with observed outcomes at the provider and clinic levels. After completion of each phase, we will send all providers at our partner clinics a survey to assess their exposure to and experience with the intervention component. Furthermore, we will evaluate the changes in organizational culture and climate that may ascertain potential mechanisms of impact using the 29 survey items we developed based on the CFIR. C7. Data Analysis Plan We will conduct descriptive analyses, as well as within-group and between-group changes over time. Furthermore, to evaluate the four-component intervention effects, we will take a step-by-step approach. First, each intervention effect at each time phase will be estimated separately using linear-mixed effects models. The estimate of intervention effect in each model will be used to test if additional intervention component significantly affects outcome measures. Next, we will develop a grand model, including all intervention components simultaneously, in addition to the models described above.
Interventions
In Phase 1, CRC control experts will identify critical messages on CRC, screening guidelines, and methods, and provide educational training to providers and staff in our partner FQHCs before implementing any intervention components. Additionally, the research team will provide refresher sessions and offer yearly training in CRC-relevant topics, including CRC and genetics.
In Phase 2, we will add a patient reminder component using short message services (SMS) to engage and remind patients to complete the screening. For patients who use colonoscopy as a screening method, the SMS will also include instructions on bowel preparation and dietary restrictions for five days prior to the procedure.
In Phase 3, we will add patient navigation services, which will address both organizational and individual barriers to obtaining screening.
Sponsors
Study design
Eligibility
Inclusion criteria
Eligibility for Federally Qualified Health Centers (FQHCs) Inclusion criteria: * Located in Illinois or Indiana * Provide adult primary care * Serve patients between the ages of 50 and 75 years * Able to provide patient-level data
Exclusion criteria
* Located outside Illinois or Indiana * Do not provide adult primary care * Unable to provide patient-level data Eligibility for patients whom our FQHC partners serve: Inclusion criteria: * Between the ages of 50 and 75 * At general risk for colorectal cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CRC Screening Rate | From date of randomization until the last subject completed the study. This could have been up to 36 months. | The number of patients aged 50-75 years who were up-to-date with colorectal cancer screening during each implementation phase. |
| CRC Screening Ordering Rate | From date of randomization until the date subject completed the study. This could have been up to 36 months. | The number of patients between the ages of 50 and 75 who needed CRC screening and received a screening order (excluding participants who received an order but have already been up to date with screening ) during each implementation phase. |
| CRC Screening Completion Rate | From date of randomization until the date subject completed the study. This could have been up to 36 months. | The number of patients between the ages of 50 and 75 who needed CRC screening, received an order for screening, and completed the screening during each implementation phase. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Provider Education Participation | From the date of the first education session until the completion of the last education sessions. This could have been up to 24 months. | The number of providers who attended the annual education sessions during Phase 1 and Phase 2. To accommodate the COVID-19 restrictions, all sessions were delivered via Zoom, with multiple sessions scheduled within each FQHC based on clinic availability. Both groups received the education component simultaneously, with no delay in implementation. |
| Patient Reminder Enrollment | From the initiation of the SMS reminder system until the last participant enrolled. This could have been up to 30 months. | The number of participants who received a FIT or colonoscopy order (excluding Cologuard, which provides its own reminder services) and subsequently enrolled in the short message service (SMS) reminder system during Phase 2 and Phase 3. The SMS platform was used to engage participants and remind them to complete their screenings; participants could opt out at any time by replying STOP. |
| Impact of Remote Patient Navigation Services | From the navigation service initiated at the partner FQHC until the completion of the study, assessed up to 16 months. | The number of participants who received remote navigation services (phone-based navigation) during Phase 3 and subsequently completed their screenings. |
Countries
United States
Participant flow
Recruitment details
The study recruited four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. Together, these four FQHCs operate 65 primary care clinics and served 131,233 individual patients in 2020. One FQHC from each state was randomly assigned to Group 1, while the remaining two were assigned to Group 2. Both groups received the intervention; the only distinction was that implementation in Group 2 was delayed by three months compared to Group 1.
Participants by arm
| Arm | Count |
|---|---|
| Group 1 The study was conducted at 4 federally qualified health centers (FQHCs): 2 in Illinois and 2 in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components, except that Group 2 began the intervention 3 months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting.
The intervention consists of three components:
1. Provider and staff education,
2. Patient reminders using short message services (SMS), and
3. Remote patient navigation (PN).
Implementation was phased as follows:
* Phase 0: No intervention components, baseline data collection only
* Phase 1: Component 1 only
* Phase 2: Components 1 + 2
* Phase 3: Components 1 + 2 +3
Baseline data collection was restricted to patients aged 50-75 years, the age group eligible for colorectal cancer screening in 2020. While provider and staff education sessions were part of the intervention components, no provider or staff characteristics were collected per protocol. | 18,099 |
| Group 1 The study was conducted at 4 federally qualified health centers (FQHCs): 2 in Illinois and 2 in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components, except that Group 2 began the intervention 3 months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting.
The intervention consists of three components:
1. Provider and staff education,
2. Patient reminders using short message services (SMS), and
3. Remote patient navigation (PN).
Implementation was phased as follows:
* Phase 0: No intervention components, baseline data collection only
* Phase 1: Component 1 only
* Phase 2: Components 1 + 2
* Phase 3: Components 1 + 2 +3
Baseline data collection was restricted to patients aged 50-75 years, the age group eligible for colorectal cancer screening in 2020. While provider and staff education sessions were part of the intervention components, no provider or staff characteristics were collected per protocol. | 2 |
| Group 2 The study was conducted at 4 federally qualified health centers (FQHCs): 2 in Illinois and 2 in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components, except that Group 2 began the intervention 3 months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting.
The intervention consists of three components:
1. Provider and staff education,
2. Patient reminders using short message services (SMS), and
3. Remote patient navigation (PN).
Implementation was phased as follows:
* Phase 0: No intervention components, baseline data collection only
* Phase 1: Component 1 only
* Phase 2: Components 1 + 2
* Phase 3: Components 1 + 2 +3
Baseline data collection was restricted to patients aged 50-75 years, the age group eligible for colorectal cancer screening in 2020. While provider and staff education sessions were part of the intervention components, no provider or staff characteristics were collected per protocol. | 20,834 |
| Group 2 The study was conducted at 4 federally qualified health centers (FQHCs): 2 in Illinois and 2 in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components, except that Group 2 began the intervention 3 months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting.
The intervention consists of three components:
1. Provider and staff education,
2. Patient reminders using short message services (SMS), and
3. Remote patient navigation (PN).
Implementation was phased as follows:
* Phase 0: No intervention components, baseline data collection only
* Phase 1: Component 1 only
* Phase 2: Components 1 + 2
* Phase 3: Components 1 + 2 +3
Baseline data collection was restricted to patients aged 50-75 years, the age group eligible for colorectal cancer screening in 2020. While provider and staff education sessions were part of the intervention components, no provider or staff characteristics were collected per protocol. | 2 |
| Total | 38,937 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Step 2 (Months 19-21) | In a 3-month delay period | 0 | 15,725 |
| Step 4 (Months 31-33) | In a 3-month delay period | 0 | 15,037 |
Baseline characteristics
| Characteristic | Group 2 | Total | Group 1 |
|---|---|---|---|
| Age, Continuous FQHC 1 | 58.77 years STANDARD_DEVIATION 6.138 | 58.96 years STANDARD_DEVIATION 6.195 | 59.25 years STANDARD_DEVIATION 6.272 |
| Age, Continuous FQHC 2 | 59.45 years STANDARD_DEVIATION 6.126 | 59.79 years STANDARD_DEVIATION 6.275 | 60.04 years STANDARD_DEVIATION 6.374 |
| Colorectal Cancer (CRC) Screening Up-to-date Rate FQHC 1: CRC Screening Up to Date | 2203 Participants | 5201 Participants | 2998 Participants |
| Colorectal Cancer (CRC) Screening Up-to-date Rate FQHC 2: CRC Screening Up to Date | 1817 Participants | 6456 Participants | 4639 Participants |
| CRC Order Rate FQHC 1: CRC Screening Order Rate | 3405 Participants | 5209 Participants | 1804 Participants |
| CRC Order Rate FQHC 2: CRC Screening Order Rate | 884 Participants | 4254 Participants | 3370 Participants |
| CRC Screening Completion Rate FQHC 1: CRC Screening Completion Rate | 1320 Participants | 2031 Participants | 711 Participants |
| CRC Screening Completion Rate FQHC 2: CRC Screening Completion Rate | 344 Participants | 2016 Participants | 1672 Participants |
| Ethnicity (NIH/OMB) FQHC 1 Hispanic or Latino | 3859 Participants | 6670 Participants | 2811 Participants |
| Ethnicity (NIH/OMB) FQHC 1 Not Hispanic or Latino | 8306 Participants | 13188 Participants | 4882 Participants |
| Ethnicity (NIH/OMB) FQHC 1 Unknown or Not Reported | 1741 Participants | 2991 Participants | 1250 Participants |
| Ethnicity (NIH/OMB) FQHC 2 Hispanic or Latino | 664 Participants | 1959 Participants | 1295 Participants |
| Ethnicity (NIH/OMB) FQHC 2 Not Hispanic or Latino | 3316 Participants | 7514 Participants | 4198 Participants |
| Ethnicity (NIH/OMB) FQHC 2 Unknown or Not Reported | 2948 Participants | 6611 Participants | 3663 Participants |
| Race (NIH/OMB) FQHC 1 American Indian or Alaska Native | 616 Participants | 684 Participants | 68 Participants |
| Race (NIH/OMB) FQHC 1 Asian | 177 Participants | 252 Participants | 75 Participants |
| Race (NIH/OMB) FQHC 1 Black or African American | 5111 Participants | 9551 Participants | 4440 Participants |
| Race (NIH/OMB) FQHC 1 More than one race | 1636 Participants | 2352 Participants | 716 Participants |
| Race (NIH/OMB) FQHC 1 Native Hawaiian or Other Pacific Islander | 75 Participants | 109 Participants | 34 Participants |
| Race (NIH/OMB) FQHC 1 Unknown or Not Reported | 1886 Participants | 3164 Participants | 1278 Participants |
| Race (NIH/OMB) FQHC 1 White | 4405 Participants | 6737 Participants | 2332 Participants |
| Race (NIH/OMB) FQHC 2 American Indian or Alaska Native | 77 Participants | 119 Participants | 42 Participants |
| Race (NIH/OMB) FQHC 2 Asian | 93 Participants | 159 Participants | 66 Participants |
| Race (NIH/OMB) FQHC 2 Black or African American | 1699 Participants | 3016 Participants | 1317 Participants |
| Race (NIH/OMB) FQHC 2 More than one race | 66 Participants | 259 Participants | 193 Participants |
| Race (NIH/OMB) FQHC 2 Native Hawaiian or Other Pacific Islander | 28 Participants | 39 Participants | 11 Participants |
| Race (NIH/OMB) FQHC 2 Unknown or Not Reported | 599 Participants | 909 Participants | 310 Participants |
| Race (NIH/OMB) FQHC 2 White | 4366 Participants | 11583 Participants | 7217 Participants |
| Region of Enrollment United States | 20834 participants | 38933 participants | 18099 participants |
| Sex/Gender, Customized FQHC 1 Female | 7478 Participants | 12497 Participants | 5019 Participants |
| Sex/Gender, Customized FQHC 1 Male | 5651 Participants | 8989 Participants | 3338 Participants |
| Sex/Gender, Customized FQHC 1 Unknown | 777 Participants | 1363 Participants | 586 Participants |
| Sex/Gender, Customized FQHC 2 Female | 4105 Participants | 9450 Participants | 5345 Participants |
| Sex/Gender, Customized FQHC 2 Male | 2823 Participants | 6629 Participants | 3806 Participants |
| Sex/Gender, Customized FQHC 2 Unknown | 0 Participants | 5 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 18,099 | 0 / 20,834 | 0 / 19,318 | 0 / 18,878 | 0 / 21,102 | 0 / 15,725 | 0 / 21,602 | 0 / 15,037 |
| other Total, other adverse events | 0 / 18,099 | 0 / 20,834 | 0 / 19,318 | 0 / 18,878 | 0 / 21,102 | 0 / 15,725 | 0 / 21,602 | 0 / 15,037 |
| serious Total, serious adverse events | 0 / 18,099 | 0 / 20,834 | 0 / 19,318 | 0 / 18,878 | 0 / 21,102 | 0 / 15,725 | 0 / 21,602 | 0 / 15,037 |
Outcome results
CRC Screening Completion Rate
The number of patients between the ages of 50 and 75 who needed CRC screening, received an order for screening, and completed the screening during each implementation phase.
Time frame: From date of randomization until the date subject completed the study. This could have been up to 36 months.
Population: The overall number represents all participants who needed CRC screening and received an order across all study phases. The number analyzed reflects only participants contributing data at the reported milestone.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1 | CRC Screening Completion Rate | Phase 1: Provider and Staff Educatioin | 3106 Participants |
| Group 1 | CRC Screening Completion Rate | Phase 2: Provider and Staff Education + Patient Reminders | 3031 Participants |
| Group 1 | CRC Screening Completion Rate | Phase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation | 3278 Participants |
| Group 2 | CRC Screening Completion Rate | Phase 1: Provider and Staff Educatioin | 1917 Participants |
| Group 2 | CRC Screening Completion Rate | Phase 2: Provider and Staff Education + Patient Reminders | 1749 Participants |
| Group 2 | CRC Screening Completion Rate | Phase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation | 1691 Participants |
CRC Screening Ordering Rate
The number of patients between the ages of 50 and 75 who needed CRC screening and received a screening order (excluding participants who received an order but have already been up to date with screening ) during each implementation phase.
Time frame: From date of randomization until the date subject completed the study. This could have been up to 36 months.
Population: The overall number represents all participants who needed screening across all study Phases. The number analyzed reflects only participants contributing data at the reported phase.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1 | CRC Screening Ordering Rate | Phase 1: Provide and Staff Education | 7012 Participants |
| Group 1 | CRC Screening Ordering Rate | Phase 2: Provider and Staff Education + Patient Reminders | 6458 Participants |
| Group 1 | CRC Screening Ordering Rate | Phase 3: Provide and Staff Education + Patient Reminders + Remote Patient Navigation | 6478 Participants |
| Group 2 | CRC Screening Ordering Rate | Phase 1: Provide and Staff Education | 5087 Participants |
| Group 2 | CRC Screening Ordering Rate | Phase 2: Provider and Staff Education + Patient Reminders | 4757 Participants |
| Group 2 | CRC Screening Ordering Rate | Phase 3: Provide and Staff Education + Patient Reminders + Remote Patient Navigation | 4611 Participants |
CRC Screening Rate
The number of patients aged 50-75 years who were up-to-date with colorectal cancer screening during each implementation phase.
Time frame: From date of randomization until the last subject completed the study. This could have been up to 36 months.
Population: The overall number represents all participants across all study phases. The number analyzed reflects only participants contributing data at the reported phase.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1 | CRC Screening Rate | Phase 1: Provider and Staff Education | 8611 Participants |
| Group 1 | CRC Screening Rate | Phase 2: Provider Education + Patient Reminder | 9438 Participants |
| Group 1 | CRC Screening Rate | Phase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation | 10720 Participants |
| Group 2 | CRC Screening Rate | Phase 1: Provider and Staff Education | 3989 Participants |
| Group 2 | CRC Screening Rate | Phase 2: Provider Education + Patient Reminder | 3186 Participants |
| Group 2 | CRC Screening Rate | Phase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation | 3303 Participants |
Impact of Remote Patient Navigation Services
The number of participants who received remote navigation services (phone-based navigation) during Phase 3 and subsequently completed their screenings.
Time frame: From the navigation service initiated at the partner FQHC until the completion of the study, assessed up to 16 months.
Population: The overall number represents the number of participants whom the navigators successfully contacted and spoke to during Phase 3.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 1 | Impact of Remote Patient Navigation Services | 529 Participants |
| Group 2 | Impact of Remote Patient Navigation Services | 284 Participants |
Patient Reminder Enrollment
The number of participants who received a FIT or colonoscopy order (excluding Cologuard, which provides its own reminder services) and subsequently enrolled in the short message service (SMS) reminder system during Phase 2 and Phase 3. The SMS platform was used to engage participants and remind them to complete their screenings; participants could opt out at any time by replying STOP.
Time frame: From the initiation of the SMS reminder system until the last participant enrolled. This could have been up to 30 months.
Population: The overall number represents the total number of participants who received a FIT or colonoscope order during the implementation of Phase 1 and Phase 2. The number analyzed reflects only the number of participants contributing data to the reported milestone.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1 | Patient Reminder Enrollment | Phase 2: Provider and Staff Education + Patient Reminders | 4756 Participants |
| Group 1 | Patient Reminder Enrollment | Phase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation | 5198 Participants |
| Group 2 | Patient Reminder Enrollment | Phase 2: Provider and Staff Education + Patient Reminders | 4693 Participants |
| Group 2 | Patient Reminder Enrollment | Phase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation | 3943 Participants |
Provider Education Participation
The number of providers who attended the annual education sessions during Phase 1 and Phase 2. To accommodate the COVID-19 restrictions, all sessions were delivered via Zoom, with multiple sessions scheduled within each FQHC based on clinic availability. Both groups received the education component simultaneously, with no delay in implementation.
Time frame: From the date of the first education session until the completion of the last education sessions. This could have been up to 24 months.
Population: The overall number represents the total number of providers invited to the education sessions during Phase 1 and Phase 2. The number analyzed reflects the number of providers invited to the education sessions during the reported phase.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1 | Provider Education Participation | Phase 1: Provider and Staff Education | 129 Participants |
| Group 1 | Provider Education Participation | Phase 2: Provider and Staff Education + Patient Reminders | 126 Participants |
| Group 2 | Provider Education Participation | Phase 1: Provider and Staff Education | 44 Participants |
| Group 2 | Provider Education Participation | Phase 2: Provider and Staff Education + Patient Reminders | 89 Participants |